Curis shrinks head­count by 30% as ex­ecs place big­ger hopes on blood can­cer drug

Now that it’s got­ten both clin­i­cal holds lift­ed for the blood can­cer drug emavusert­ib, Curis is ready to move full speed ahead.

But first, it’s go­ing to prune the pipeline — with a wave of lay­offs to fol­low.

The Lex­ing­ton, MA-based biotech re­vealed in its Q3 up­date that as it con­cen­trates on the de­vel­op­ment of emavusert­ib, it’s re­al­lo­cat­ing re­sources and de­pri­or­i­tiz­ing oth­er pro­grams. As a re­sult, it’s shrink­ing the work­force by 30%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER